Ariel Investments, an investment management company, released its “Ariel Focus Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. Ariel Focus Fund delivered mixed results in the fourth quarter of 2025, declining -0.50% and underperforming both the S&P 500 and Russell 1000 Value indices, which gained +2.66% and +3.81%, respectively, although the fund outperformed both benchmarks over the full year with a +20.97% return. The quarter took place in a resilient U.S. market environment marked by easing inflation, stable corporate earnings, and growing optimism around accommodative monetary policy, alongside continued strength in artificial intelligence and cloud-driven technology stocks, despite volatility stemming from geopolitical risks, labor market softening, and earlier-year disruptions. The fund maintained a disciplined, long-term, bottom-up investment approach, adding selectively to positions such as a security solutions provider while refraining from exits during the quarter. Looking ahead, management remains cautiously optimistic but highlights elevated market concentration, valuation risks in large-cap leaders, and macro uncertainties, emphasizing that increasing dispersion and evolving market leadership should create opportunities for active investors focused on companies with strong balance sheets, durable earnings, competitive advantages, and long-term structural growth potential. In addition, please check the Fund’s top five holdings to know its best picks in 2025.
In its fourth-quarter 2025 investor letter, Ariel Focus Fund highlighted stocks like Johnson & Johnson (NYSE:JNJ). Johnson & Johnson (NYSE:JNJ) is a diversified healthcare company that develops pharmaceuticals and medical technologies focused on improving patient outcomes worldwide. The one-month return of Johnson & Johnson (NYSE:JNJ) was -1.73% while its shares traded between $141.50 and $251.71 over the last 52 weeks. On March 30, 2026, Johnson & Johnson (NYSE:JNJ) stock closed at approximately $242.49 per share, with a market capitalization of about $584.38 billion.
Ariel Focus Fund stated the following regarding Johnson & Johnson (NYSE:JNJ) in its Q4 2025 investor letter:
“Additionally, consumer healthcare company, Johnson & Johnson (NYSE:JNJ) traded up on strong earnings and a raise in full-year revenue guidance. With a sharpened focus on six priority areas—Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision—the company is entering a new era of accelerated growth and innovation. Performance was augmented by key growth products like Carvykti, promising new data for Rybrevant and more favorable erosion trends for legacy franchises. Management reaffirmed confidence in long-term prospects, supported by pioneering treatments and a robust pipeline. We continue to view JNJ as an attractive opportunity in large-cap biopharma, given its scale, innovation and consistent execution.”
Emilio100 / Shutterstock.com
Johnson & Johnson (NYSE:JNJ) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. As per our database, 104 hedge fund portfolios held Johnson & Johnson (NYSE:JNJ) at the end of the fourth quarter, which was 103 in the previous quarter. While we acknowledge the risk and potential of Johnson & Johnson (NYSE:JNJ) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Johnson & Johnson (NYSE:JNJ) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered Johnson & Johnson (NYSE:JNJ) and shared the list of stocks that were discussed by Jim Cramer. In addition, please check out our hedge fund investor letters Q4 2025 page for more investor letters from hedge funds and other leading investors.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. This article is originally published at Insider Monkey.
